Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Long-Acting pill could smooth Parkinson's symptoms

NCT ID NCT05036473

Disease control Sponsor: Shanghai WD Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This study tests an extended-release tablet containing carbidopa and levodopa (WD-1603) for people with early Parkinson's disease. The goal is to see if taking the medication three times daily improves motor symptoms and daily living better than a placebo. The trial involves 40 adults aged 30–75 with mild to moderate Parkinson's and compares the drug's effects over 27 days.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
WD-1603 (carbidopa-levodopa extended-release tablets)
What this could lead to
If successful, this extended-release formulation could provide more stable symptom control for people with early Parkinson's disease, reducing motor fluctuations.
What could go wrong
This is an early phase 2 trial with only 40 participants, so results may not apply to all patients. The drug may cause side effects like nausea or dizziness, and it is not a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

40 people

The number who actually took part.

Started

Nov 2021

Finished

Dec 2022

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male/female patients with early Parkinson's disease who are over 30 years old and under 75 years old (including cut-off values). 2. Able to understand and willing to sign an informed consent form (ICF) voluntarily. 3. The diagnosis of Parkinson's disease complies with idiopathic Parkinson's disease (2015 version of MDS Parkinson's disease diagnostic criteria). 4. Modified Hoehn and Yahr Scale≥1, ≤2.5 points. 5. Agree to use medically acceptable contraceptive methods throughout the study and within 1 month after completing the study. Exclusion Criteria: 1. Have a history of severe allergic reactions or allergies to levodopa or carbidopa. 2. Pregnancy or breastfeeding. 3. Diagnosed as atypical Parkinson's disease or any known secondary Parkinson's syndrome. 4. The investigator believes that the placebo treatment cannot be tolerated. 5. Acute psychosis or hallucinations, using any antipsychotic to treat psychosis or clinically obvious depression. 6. History of epilepsy or epilepsy. 7. The history of narrow-angle glaucoma. 8. Subjects with a history of malignant melanoma. 9. Patients with obvious cognitive impairment. 10. The investigator believes that there are clinically significant medical or surgical diseases and patients who are not suitable for participating in clinical trials.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson disease

Contacts and locations

Locations

  • Shanghai Huashan Hospital

    Shanghai, Shanghai Municipality, 200040, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.